DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pneumocystosis — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePneumocystosis maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pneumocystosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 3 subfamily A member 4 (CYP3A4) — CYP3A4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5VCC · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Pneumocystosis is primarily a lung disease, but extrapulmonary dissemination may be a common part of the natural course of infection rather than an exceptional event. In a 1997 study of 12 immunosuppressed rats and two immunocompetent rats, Pneumocystis carinii DNA was detected by PCR in the lungs of all 14 animals. At least one organ other than the lung was positive in 11 of the immunosuppressed rats and in both control rats. The authors concluded that dissemination is not rare.
Recurrent pneumocystosis in a single patient has been attributed to reinfection rather than reactivation of latent disease. A 2012 case report based on molecular typing of Pneumocystis jirovecii from a haemato-oncology patient with recurrent episodes supported the hypothesis that each episode was caused by a new infection acquired de novo.
A 2022 autopsy case report describes a generalised form of pneumocystis infection in an immunocompromised patient. Clinical features included febrile fever, intoxication, non-productive cough, shortness of breath on little exertion, elevated hepatic transaminases, and leukocytosis. Histological examination revealed pneumocystis foci at various developmental stages in the parenchyma and interstitium of the liver, kidneys, spleen, brain, red bone marrow, lungs, and uterus. The authors note that this generalised form is very rare, has a long asymptomatic period, and is difficult to diagnose by laboratory methods, so mortality is constantly increasing. They list differential diagnoses including acute respiratory infections, cytomegalovirus, mycoplasmosis, chlamydia, toxoplasmosis, tuberculosis, sarcoidosis, neoplasms, lymphogranulomatosis, and collagenoses, and recommend ELISA, indirect immunofluorescence, immunofluorescence, and PCR for precise diagnosis.
What is still missing are prospective clinical studies that track dissemination in living patients, validated diagnostic criteria for extrapulmonary and generalised pneumocystosis, and any controlled trial data on treatment strategies for these forms. The evidence rests on small animal experiments, single case reports, and autopsy series.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Microbiology · 1997 · 10 citations
Detection of Pneumocystis carinii DNA by PCR amplification in various rat organs in experimental pneumocystosis
AbstractPneumocystosis is usually a disease of the lungs, but the number of cases of extrapulmonary pneumocystosis has greatly increased during the AIDS epidemic. Much remains unknown about the frequency and mechanisms of dissemination. In the present study, a systematic search for Pneumocystis carinii by PCR with primers specific for mitochondrial rRNA was performed in the lung, liver, spleen and kidney of 12 immunosuppressed rats and two immunocompetent rats. The amplified products were analysed by Southern hybridisation with a digoxigenin-11-dUTP labeled probe. P. carinii DNA was found in lungs in all 14 rats and in at least one organ other than lung in 11 immunosuppressed rats and the two control rats. We suggest that extrapulmonary dissemination may not be an exceptional phenomenon in the course of pneumocystosis, but rather part of the natural evolution of the disease.
Scandinavian Journal of Infectious Diseases · 2012 · 2 citations
Molecular evidence of Pneumocystis jirovecii reinfection in a haemato-oncology patient
AbstractFor many years Pneumocystis pneumonia was thought to be caused by the reactivation of a latent infection, but several studies have demonstrated that Pneumocystis jirovecii infection can be acquired de novo. On the basis of our results obtained from a patient with recurrent pneumocystosis, we support the hypothesis that recurrent episodes are caused by reinfection.
PNEUMOCYSTIS CHRONIOSEPSIS AS AN OPTION OF PNEUMOCYSTIS INFECTION PROGRESSION: CASE REPORT
AbstractPneumocystis infection caused by Pneumocystis jiroveci tops the list of opportunistic infections, affecting mainly premature babies and people with various types of immunodeficiency disorders. Generalized forms of the disease in immunocompromised patients are extremely rare and do not have any pathognomonic symptoms, which often makes timely diagnosis and treatment difficult. The aim of the paper is to study clinical and morphological manifestations of generalized pneumocystosis and to clarify some aspects of its differential diagnosis as illustrated by an autopsy case. Materials and Methods. For histomorphological examination, autopsies of the liver, lung, pancreas, red bone marrow, brain, heart, and spleen were fixed in 10 % neutral formalin and embedded in paraffin. Sections of standard thickness were stained with hematoxylin-eosin; then histologic specimen were studied under a light microscope. The results of the histomorphological study were analyzed along with the medical history. Results. It has been shown that the following nonspecific clinical manifestations were specifically attributed to the generalized form of pneumocystosis: febrile fever, intoxication, non-productive cough, shortness of breath on little exertion, increased levels of hepatic transaminases, and leukocytosis. Histological manifestations included pneumocystis foci at different stages of development both in the parenchyma and in the interstitium of many internal organs, such as the liver, kidneys, spleen, brain, red bone marrow, lungs, and uterus. The preservation of the organ histoarchitectonics depended on the number of pneumocystis foci and the degree of organ damage. Conclusion. The generalized form of pneumocystis infection is very rare and it can be combined with other concomitant diseases. Moreover, it is characterized by a long asymptomatic period and complexity of laboratory diagnostics, so its mortality constantly increases. Generalized form of pneumocystis infection should be differentiated from acute respiratory diseases, cytomegalovirus infection, mycoplasmosis, chlamydia, toxoplasmosis, tuberculosis, sarcoidosis, neoplastic diseases, lymphogranulomatosis, and collagenoses, where the most precise methods are ELISA, indirect immunofluorescence test, immunofluorescence test, and PCR.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
